{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:59:27Z","timestamp":1792511967989,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Coronaviruses frequently undergo genomic mutation and recombination in nature. Through cross-species infection and sporadic spillover events, novel coronaviruses may periodically emerge in humans. SARS-CoV-1, MERS-CoV, and SARS-CoV-2 all cause severe, predominantly respiratory diseases with moderate to high pathogenicity, posing a substantial threat to public health. To prepare for potential future coronavirus outbreaks, there is a need for universal vaccines capable of eliciting broad-spectrum humoral and cellular immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we constructed DNA- and replicating Vaccinia virus TianTan (VTT)-vectored monovalent and trivalent vaccines, using the spike (S) proteins of the aforementioned wild-type viruses as immunogens in a heterologous DNA-prime\/VTT-boost regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with monovalent vaccines, the trivalent candidate induced robust, broad-spectrum humoral and cellular immune responses against the S proteins of SARS-CoV-1, MERS-CoV, and SARS-CoV-2 in mice. Notably, it also conferred protection against challenge with the SARS-CoV-2 XBB variant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings offer important insights for developing practical multivalent coronavirus vaccines that could help mitigate transmission and mortality early in future coronavirus outbreaks. Such an initial countermeasure could buy critical time for the development of variant-specific vaccines and further inform the design of universal coronavirus vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1734382","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:19:00Z","timestamp":1769411940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Trivalent coronavirus vaccines elicit broad-spectrum immunity in mice and attenuate respiratory viral load in golden hamsters"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiuli","family":"Shen","sequence":"first","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]},{"name":"Changping Laboratory","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangshan","family":"He","sequence":"additional","affiliation":[{"name":"Changping Laboratory","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoshun","family":"Liu","sequence":"additional","affiliation":[{"name":"Changping Laboratory","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Changping Laboratory","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijia","family":"Wang","sequence":"additional","affiliation":[{"name":"Changping Laboratory","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Shao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]},{"name":"Changping Laboratory","place":["Beijing, China"]},{"name":"School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1458383","article-title":"Structural proteins of human coronaviruses: what makes them different","volume":"14","author":"Minigulov","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0060123","DOI":"10.1128\/jvi.00601-23","article-title":"Characterization of CCoV-HuPn-2018 spike protein-mediated viral entry","volume":"97","author":"Liu","year":"2023","journal-title":"J Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab456","article-title":"Novel canine coronavirus isolated from a hospitalized patient with pneumonia in east Malaysia","volume":"74","author":"Vlasova","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e70171","DOI":"10.1002\/jmv.70171","article-title":"Rapid generation of reverse genetics systems for coronavirus research and high-throughput antiviral screening using gibson DNA assembly","volume":"97","author":"Zhou","year":"2025","journal-title":"J Med Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04111-z","article-title":"Independent infections of porcine deltacoronavirus among Haitian children","volume":"600","author":"Lednicky","year":"2021","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00023-07","article-title":"Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection","volume":"20","author":"Cheng","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2016.81","article-title":"recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.cell.2024.12.031","article-title":"Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses","volume":"188","author":"Ma","year":"2025","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"115760","DOI":"10.1016\/j.celrep.2025.115760","article-title":"Designed miniproteins potently inhibit and protect against MERS-CoV","volume":"44","author":"Ragotte","year":"2025","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0020764020915212","article-title":"The outbreak of COVID-19 coronavirus and its impact on global mental health","volume":"66","author":"Torales","year":"2020","journal-title":"Int J Soc Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41392-020-0190-2","article-title":"Overview of lethal human coronaviruses","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04188-6","article-title":"The emergence, genomic diversity and global spread of SARS-CoV-2","volume":"600","author":"Li","year":"2021","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2004-127","article-title":"Coronaviruses and SARS-COV-2","volume":"50","author":"Hasoksuz","year":"2020","journal-title":"Turk J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-corV, with potent protection against SARS-coV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae329","article-title":"Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1\/2 randomized trial","volume":"231","author":"Ananworanich","year":"2025","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41392-025-02259-y","article-title":"Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41541-025-01094-0","article-title":"Efficacy of emergency maternal MVA-ZIKV vaccination in a rapid challenge model of lethal Zika infection","volume":"10","author":"Volz","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.virs.2024.05.005","article-title":"DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice","volume":"39","author":"Shen","year":"2024","journal-title":"Virol Sin"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101110","DOI":"10.1016\/j.omtm.2023.101110","article-title":"A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection","volume":"31","author":"Boulton","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2217\/fvl-2023-0212","article-title":"Exploration of the cross-immunity between SARS-CoV and SARS-CoV-2 in mice","volume":"19","author":"Wang","year":"2024","journal-title":"Future Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1099991","article-title":"A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice","volume":"13","author":"Bai","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0394-5","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay","volume":"15","author":"Nie","year":"2020","journal-title":"Nat Protoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf6840","article-title":"Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice","volume":"371","author":"Cohen","year":"2021","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1016\/j.cell.2024.07.052","article-title":"Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals","volume":"187","author":"Cohen","year":"2024","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0066824","DOI":"10.1128\/mbio.00668-24","article-title":"A decavalent composite mRNA vaccine against both influenza and COVID-19","volume":"15","author":"Wang","year":"2024","journal-title":"Mbio"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1012508","DOI":"10.1371\/journal.ppat.1012508","article-title":"A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants","volume":"20","author":"Hao","year":"2024","journal-title":"PloS Pathog"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2303366","DOI":"10.1002\/advs.202303366","article-title":"Mosaic RBD nanoparticles elicit protective immunity against multiple human coronaviruses in animal models","volume":"11","author":"Zhang","year":"2023","journal-title":"Adv Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00838-5","article-title":"T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant","volume":"19","author":"Choi","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1473428","article-title":"A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.chom.2024.10.016","article-title":"A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice","volume":"32","author":"Case","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e184074","DOI":"10.1172\/jci.insight.184074","article-title":"Tissue-resident memory T cells contribute to protection against heterologous SARS-CoV-2 challenge","volume":"9","author":"Odle","year":"2024","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01743-x","article-title":"Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection","volume":"25","author":"Ying","year":"2024","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.978440","article-title":"Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination","volume":"12","author":"Hu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac057","article-title":"Severe acute respiratory syndrome coronavirus 2 vaccination boosts neutralizing activity against seasonal human coronaviruses","volume":"75","author":"Lawrenz","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/vaccines13040424","article-title":"Beyond the pandemic era: recent advances and efficacy of SARS-coV-2 vaccines against emerging variants of concern","volume":"13","author":"Saha","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1","volume":"637","author":"Jian","year":"2024","journal-title":". Nat"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0350324","DOI":"10.1128\/mbio.03503-24","article-title":"Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3","volume":"16","author":"Hu","year":"2025","journal-title":"Mbio"},{"key":"B41","doi-asserted-by":"publisher","first-page":"114520","DOI":"10.1016\/j.celrep.2024.114520","article-title":"Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants","volume":"44","author":"Li","year":"2024","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2313681121","DOI":"10.1073\/pnas.2313681121","article-title":"Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5\/35 platform","volume":"121","author":"Chang","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/s1473-3099(24)00565-6","article-title":"Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4\/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4\/5 mRNA vaccine: a randomised phase 3 trial","volume":"25","author":"Okada","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(24)00077-x","article-title":"Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial","volume":"24","author":"Bennett","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/vaccines12121300","article-title":"Safety, immunogenicity and protective activity of a modified trivalent live attenuated influenza vaccine for combined protection against seasonal influenza and COVID-19 in golden Syrian hamsters","volume":"12","author":"Stepanova","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1381508","article-title":"Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response","volume":"15","author":"Mazunina","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0037624","DOI":"10.1128\/jvi.00376-24","article-title":"Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge","volume":"98","author":"Wang","year":"2024","journal-title":"J Virol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"113248","DOI":"10.1016\/j.celrep.2023.113248","article-title":"Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice","volume":"42","author":"Martinez","year":"2023","journal-title":"Cell Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1093\/infdis\/jiad508","article-title":"Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-coV-2 recombinant spike protein booster vaccines: A phase 3 randomized clinical trial","volume":"230","author":"Bennett","year":"2024","journal-title":"J Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.049","article-title":"A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants","volume":"42","author":"Song","year":"2024","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:19:01Z","timestamp":1769411941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1734382"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1734382","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1734382"}}